Harmony Biosciences Holdings, Inc. provided revenue guidance for the year 2024. For the year, the company expects net product revenue to be between $700 million to $720 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.4 USD | -2.83% | -3.45% | -5.63% |
04-30 | Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise | MT |
04-30 | Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.63% | 1.78B | |
+30.63% | 695B | |
+26.51% | 568B | |
-4.64% | 361B | |
+19.59% | 330B | |
+3.82% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.01% | 168B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024